870
Participants
Start Date
November 30, 2009
Primary Completion Date
November 30, 2011
Study Completion Date
December 31, 2011
IDP-108
Topical application once a day for 48 weeks
Vehicle
Topical application once a day for 48 weeks
Impact Clinical Trials, New Hyde Park
Penn State Milton S. Hershey Medical Center, Hershey
Temple University School of Podiatric Medicine, Philadelphia
Virginia Clinical Research, Inc, Norfolk
The Education and Research Foundation, Inc., Lynchburg
Palmetto Clinical Trial Services, LLC, Greenville
Gwinnett Clinical Research Center, Inc., Snellville
Augusta Centre for Dermatology and Skin Renewal, LLC, Augusta
Ameriderm Research, Ormond Beach
Foot and Ankle Associates of Florida, Inc, Altamonte Springs
International Dermatology Research, Inc., Miami
University of Alabama, Birmingham, Birmingham
Rivergate Dermatology, Goodlettsville
Dermatology Specialists, Louisville
Haber Dermatology & Cosmetic Surgery, South Euclid
Radiant Research, Cinncinati
Hudson Dermatology, Evansville
Michigan Center for Research Corp., Clinton Township
Aurora Advanced Healthcare, Inc. - Clinical Research Center, Milwaukee
Baylor Research Institute, Dallas
J & S Studies, Inc., College Station
Stephen Miller, MD, PA, San Antonio
Austin Dermatology Associates, Austin
Longmont Medical Research Network, Longmont
Northwest Clinical Trials, Boise
Dermatology Resarch Center, Salt Lake City
HOPE Research Institute, Phoenix
Academic Dermatology, Albuquerque
Therapeutics Clinical Research, San Diego
University Clinical Trials, Inc, San Diego
University of California, San Francisco, San Francisco
Oregon Dermatology and Research Center, Portland
The Savin Center, PC, New Haven
Kirk Barber Research, Calgary
Stratica Medical, Edmonton
Ultranova Skincare, Barrie
Mediprobe Research, New London
North Bay Dermatology Centre, North Bay
XLR8 Medical Research, Windsor
Centre de Recherche Dermatologique du Québec Métropolitain, Québec
Kaken Investigational Site, Dazaifu
Kaken Investigational Site - Chuo-ku #1, Fukuoka
Kaken Investigational Site - Chuo-ku #2, Fukuoka
Kaken Investigational Site - Higashi-ku, Fukuoka
Kaken Investigational Site - Minami-ku #1, Fukuoka
Kaken Investigational Site - Minami-ku #2, Fukuoka
Kaken Investigational Site, Itoshima
Kaken Investigational Site - Atsubetsu-ku #1, Sapporo
Kaken Investigational Site - Atsubetsu-ku #2, Sapporo
Kaken Investigational Site - Atsubetsu-ku #3, Sapporo
Kaken Investigational Site - Chuo-ku, Sapporo
Kaken Investigational Site - Kita-ku, Sapporo
Kaken Investigational Site - Kiyota-ku, Sapporo
Kaken Investigational Site - Nishi-ku, Sapporo
Kaken Investigational Site - Shiroishi-ku, Sapporo
Kaken Investigational Site - Teine-ku #1, Sapporo
Kaken Investigational Site - Teine-ku #2, Sapporo
Kaken Investigational Site, Kawasaki
Kaken Investigational Site, Nagasaki
Kaken Investigational Site, Ginowan
Kaken Investigational Site, Naha
Kaken Investigational Site, Nakagami
Kaken Investigational Site - Okinawa #1, Okinawa
Kaken Investigational Site - Okinawa #2, Okinawa
Kaken Investigational Site, Urasoe
Kaken Investigational Site, Kawaguchi
Kaken Investigational Site - Nakano-ku #1, Nakano-ku
Kaken Investigational Site - Nakano-ku #2, Nakano-ku
Kaken Investigational Site - Setagaya-ku #1, Setagaya-ku
Kaken Investigational Site - Setagaya-ku #2, Setagaya-ku
Kaken Investigational Site - Shinagawa-ku #1, Shinagawa-ku
Kaken Investigational Site - Shinagawa-ku #2, Shinagawa-ku
Lead Sponsor
Dow Pharmaceutical Sciences
INDUSTRY